Literature DB >> 12147925

Comparative effects of telmisartan in the treatment of hypertension.

William B White1.   

Abstract

Three separate randomized, double-blind, parallel-group, 12-week trials compared telmisartan with enalapril, lisinopril, and amlodipine for treating mild to moderate hypertension. Telmisartan 80 mg was associated with a significantly greater mean decrease in trough systolic and diastolic blood pressure than enalapril 20 mg (p<0.05). Mean decreases in trough systolic and diastolic blood pressure with telmisartan (40, 80, and 160 mg) and lisinopril (10, 20, and 40 mg) were similar. Telmisartan (40, 80, and 120 mg) provided greater decreases in mean hourly systolic and diastolic blood pressure throughout the 24-hour dosing interval, including the last 4 hours of the dosing period, than amlodipine (5 and 10 mg). Telmisartan was associated with a lower incidence of treatment-related cough than lisinopril and enalapril and less treatment-related angioedema than amlodipine. These data suggest that for treating mild to moderate hypertension, telmisartan has efficacy similar to lisinopril, greater efficacy than enalapril and amlodipine throughout the 24-hour dosing interval, and better tolerability than these angiotensin-converting enzyme inhibitors and amlodipine. Copyright 2002 Le Jacq Communications, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147925      PMCID: PMC8101834     

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  17 in total

1.  Cardiovascular triggers and morning events.

Authors: 
Journal:  Blood Press Monit       Date:  1998-02       Impact factor: 1.444

2.  A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine.

Authors: 
Journal:  Blood Press Monit       Date:  1998-10       Impact factor: 1.444

Review 3.  Angiotensin II receptor blockers: review of the binding characteristics.

Authors:  H Siragy
Journal:  Am J Cardiol       Date:  1999-11-18       Impact factor: 2.778

4.  Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.

Authors:  J M Neutel; W H Frishman; S Oparil; V Papademitriou; G Guthrie
Journal:  Am J Ther       Date:  1999-05       Impact factor: 2.688

5.  The incidence of cough: a comparison of lisinopril, placebo and telmisartan, a novel angiotensin II antagonist. Telmisartan Cough Study Group.

Authors:  Y Lacourciére
Journal:  Int J Clin Pract       Date:  1999-03       Impact factor: 2.503

Review 6.  Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.

Authors:  M A Weber
Journal:  J Hypertens Suppl       Date:  1997-12

7.  The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?

Authors:  Michael A Weber
Journal:  Am J Cardiol       Date:  2002-01-24       Impact factor: 2.778

8.  ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension.

Authors:  J Mallion; J Siche; Y Lacourcière
Journal:  J Hum Hypertens       Date:  1999-10       Impact factor: 3.012

9.  Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects.

Authors:  J V Gainer; J D Morrow; A Loveland; D J King; N J Brown
Journal:  N Engl J Med       Date:  1998-10-29       Impact factor: 91.245

10.  Diurnal blood pressure variations and onset of subarachnoid haemorrhage: a population-based study.

Authors:  R R Fogelholm; V M Turjanmaa; M T Nuutila; K E Murros; S Sarna
Journal:  J Hypertens       Date:  1995-05       Impact factor: 4.844

View more
  1 in total

Review 1.  Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?

Authors:  Marc P Maillard; Michel Burnier
Journal:  Vasc Health Risk Manag       Date:  2007
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.